Treatment Algorithm for Cancerous Wounds: A Systematic Review

Andrea Furka, Csaba Simkó, László Kostyál, Imre Szabó, Anikó Valikovics, Gábor Fekete, Ilona Tornyi, Endre Oross, János Révész, Andrea Furka, Csaba Simkó, László Kostyál, Imre Szabó, Anikó Valikovics, Gábor Fekete, Ilona Tornyi, Endre Oross, János Révész

Abstract

Background: In advanced cancer stage the incidence of cancerous wounds is about 5%, and the estimated life expectancy is not more than 6 to 12 months. Without interdisciplinary and individualized treatment strategy, symptoms progress, and adversely influence quality of life.

Methods: Authors collected different treatment algorithms for cancerous wound published by wide scale of medical expertise, and summarized surgical, oncological, radiation oncological, nursing and palliative care aspects based on radiological information.

Results: Interdisciplinary approach with continuous consultation between various specialists can solve or ease the hopeless cases.

Conclusions: This distressing condition needs a comprehensive treatment solution to alleviate severe symptoms. Non-healing fungating wounds without effective therapy are severe socio-economic burden for all participants, including patients, caregivers, and health services. In this paper authors collected recommendations for further guideline that is essential in the near future.

Keywords: cancerous wound; multimodal aspects; oncology; palliative care; radiotherapy; surgery; treatment algorithm.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Key terms and searching strategy flow diagram.
Figure 2
Figure 2
Multidisciplinary view of cancerous wounds treatment.

References

    1. Mortimer P. Skin problems in palliative care: Medical aspects. In: Doyle D., Hanks G., Macdonald N., editors. Oxford Textbook of Palliative Medicine. 3rd ed. Oxford Medical Publications; Oxford, UK: 1993. pp. 384–395.
    1. Grocott P. The palliative management of fungating malignant wounds. J. Wound Care. 1995;4:240–242. doi: 10.12968/jowc.1995.4.5.240.
    1. Tilley C., Lipson J., Ramos M. Palliative Wound Care for Malignant Fungating Wounds: Holistic Considerations at End-of-Life. Nurs. Clin. N. Am. 2016;51:513–531. doi: 10.1016/j.cnur.2016.05.006.
    1. Lo S.F., Hu W.Y., Hayter M., Chang S.C., Hsu M.Y., Wu L.Y. Experiences of living with a malignant fungating wound: A qualitative study. J. Clin. Nurs. 2008;17:2699–2708. doi: 10.1111/j.1365-2702.2008.02482.x.
    1. Tsichlakidou A., Govina O., Vasilopoulos G., Kavga A., Vastardi M., Kalemikerakis I. Intervention for symptom management in patients with malignant fungating wounds—A systematic review. J. Balk. Union Oncol. 2019;24:1301–1308.
    1. Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021:372. doi: 10.1136/bmj.n71.
    1. Atkinson T.M., Ryan S.J., Bennett A.V., Stover A.M., Saracino R.M., Rogak L.J., Jewell S.T., Matsoukas K., Li Y., Basch E. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): A systematic review. Support. Care Cancer. 2016;24:3669–3676. doi: 10.1007/s00520-016-3297-9.
    1. MacCarthy-Morrogh L., Martin P. The hallmarks of cancer are also the hallmarks of wound healing. Sci. Signal. 2020;13:eaay8690. doi: 10.1126/scisignal.aay8690.
    1. Chrisman C.A. Care of chronic wounds in palliative care and end-of-life patients. Int. Wound J. 2010;7:214–235. doi: 10.1111/j.1742-481X.2010.00682.x.
    1. Parsons C.M., Pimiento J.M., Cheong D., Marzban S.S., Gonzalez R.J., Johnson D., Letson G.D., Zager J.S. The role of radical amputations for extremity tumors: A single institution experience and review of the literature. J. Surg. Oncol. 2012;105:149–155. doi: 10.1002/jso.22067.
    1. Riot S., de Bonnecaze G., Garrido I., Ferron G., Grolleau J.L., Chaput B. Is the use of negative pressure wound therapy for a malignant wound legitimate in a palliative context? “The concept of NPWT ad vitam”: A case series. Palliat. Med. 2015;29:470–473. doi: 10.1177/0269216314560009.
    1. Cai S.S., Gowda A.U., Alexander R.H., Silverman R.P., Goldberg N.H., Rasko Y.M. Use of negative pressure wound therapy on malignant wounds—A case report and review of literature. Int. Wound J. 2017;14:661–665. doi: 10.1111/iwj.12665.
    1. Kalemikerakis J., Vardaki Z., Fouka G., Vlachou E., Gkovina U., Kosma E., Dionyssopoulos A. Comparison of foam dressings with silver versus foam dressings without silver in the care of malodorous malignant fungating wounds. J. Balk. Union Oncol. 2012;17:560.
    1. Lund-Nielsen B., Adamsen L., Kolmos H.J., Rørth M., Tolver A., Gottrup F. The effect of honey-coated bandages compared with silver-coated bandages on treatment of malignant wounds—A randomized study. Wound Repair Regen. 2011;19:664–670. doi: 10.1111/j.1524-475X.2011.00735.x.
    1. Lund-Nielsen B., Adamsen L., Gottrup F., Rorth M., Tolver A., Jorn Kolmos H. Qualitative bacteriology in malignant wounds--a prospective, randomized, clinical study to compare the effect of honey and silver dressings. Ostomy Wound Manag. 2011;57:28–36.
    1. Firmino F., Villela-Castro D.L., Dos Santos J., de Gouveia Santos V.L. Topical management of bleeding from malignant wounds caused by breast cancer: A systematic review. J. Pain Symptom Manag. 2021;61:1278–1286. doi: 10.1016/j.jpainsymman.2020.10.020.
    1. Villela-Castro D.L., de Gouveia Santos V.L., Woo K. Polyhexanide versus metronidazole for odor management in malignant (fungating) wounds: A double-blinded, randomized, clinical trial. J. Wound Ostomy Cont. Nurs. 2018;45:413–418. doi: 10.1097/WON.0000000000000460.
    1. Adderley U.J., Holt I.G. Topical agents and dressings for fungating wounds. Cochrane Database Syst. Rev. 2014;5:1–25. doi: 10.1002/14651858.CD003948.pub3.
    1. da Costa Santos C.M., de Mattos Pimenta C.A., Nobre M.R. A systematic review of topical treatments to control the odor of malignant fungating wounds. J. Pain Symptom Manag. 2010;39:1065–1076. doi: 10.1016/j.jpainsymman.2009.11.319.
    1. Wiese F., Kutschan S., Doerfler J., Mathies V., Buentzel J., Buentzel J., Huebner J. Green tea and green tea extract in oncological treatment: A systematic review. Int. J. Vitam. Nutr. Res. 2021:1–13. doi: 10.1024/0300-9831/a000698.
    1. Kratz A., Danon A. Controlling bleeding from superficial wounds by the use of topical alpha adrenoreceptor agonists spray. A randomized, masked, controlled study. Injury. 2004;35:1096–1101. doi: 10.1016/j.injury.2004.03.015.
    1. Marks L.B., Ten Haken R.K., Martel M.K. Guest editor’s introduction to QUANTEC: A users guide. Int. J. Radiat. Oncol. Biol. Phys. 2010;76:S1–S2. doi: 10.1016/j.ijrobp.2009.08.075.
    1. Jiang T., Zhou C. The past, present and future of immunotherapy against tumor. Transl. Lung Cancer Res. 2015;4:253–264.
    1. Tamai N., Mugita Y., Ikeda M., Sanada H. The relationship between malignant wound status and pain in breast cancer patients. Eur. J. Oncol. Nurs. 2016;24:8–12. doi: 10.1016/j.ejon.2016.05.004.
    1. Probst S., Arber A., Faithful S. Malignant fungating wounds: A survey of nurses’ clinical practice in Switzerland. Eur. J. Oncol. Nurs. 2009;13:295–298. doi: 10.1016/j.ejon.2009.03.008.
    1. Price P., Fogh K., Glynn C., Krasner D.L., Osterbrink J., Sibbald R.G. Managing painful chronic wounds: The Wound Pain Management Model. Int. Wound J. 2007;4:4–15. doi: 10.1111/j.1742-481X.2007.00311.x.
    1. Løhre E.T., Klepstad P., Bennett M.I., Brunelli C., Caraceni A., Fainsinger R.L., Knudsen A.K., Mercadante S., Sjøgren P., Kaasa S. European Association for Palliative Care Research Network. From “breakthrough” to “episodic” cancer pain? A European Association for Palliative Care Research Network Expert Delphi Survey toward a common terminology and classification of transient cancer pain exacerbations. J. Pain Symptom Manag. 2016;51:1013–1019. doi: 10.1016/j.jpainsymman.2015.12.329.
    1. Woo K.Y., Krasner D.L., Kennedy B., Wardle D., Moir O. Palliative wound care management strategies for palliative patients and their circles of care. Adv. Ski. Wound Care. 2015;28:130–140. doi: 10.1097/01.ASW.0000461116.13218.43.
    1. Briggs M., Nelson E.A., Martyn-St James M. Topical agents or dressings for pain in venous leg ulcers. Cochrane Database Syst. Rev. 2012;11:1–41. doi: 10.1002/14651858.CD001177.pub3.
    1. Finnerup N.B., Attal N., Haroutounian S., McNicol E., Baron R., Dworkin R.H., Gilron I., Haanpää M., Hansson P., Jensen T.S., et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol. 2015;14:162–173. doi: 10.1016/S1474-4422(14)70251-0.
    1. Di Stefano G., Di Lionardo A., Di Pietro G., Cruccu G., Truini A. Pharmacotherapeutic options for managing neuropathic pain: A systematic review and meta-analysis. Pain Res. Manag. 2021;2021:6656863. doi: 10.1155/2021/6656863.
    1. Afonso A.S., Carnaval T., Cés S.V. Combination therapy for neuropathic pain. A systematic review. J. Clin. Med. 2021;10:3533. doi: 10.3390/jcm10163533.
    1. Fallon M., Giusti R., Aielli F., Hoskin P., Rolke R., Sharma M., Ripamonti C.I. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann. Oncol. 2018;29:166–191. doi: 10.1093/annonc/mdy152.
    1. Rupniewska-Ładyko A. Ketamine—A unique adjuvant drug in pain treatment. Palliat. Med. Pract. 2020;14:188–193. doi: 10.5603/PMPI.2020.0023.
    1. Page N., Nirabhawane V. Intranasal Ketamine for the Management of Incidental Pain during Wound Dressing in Cancer Patients: A Pilot Study. Indian J. Palliat. Care. 2018;24:58–60. doi: 10.4103/IJPC.IJPC_143_17.
    1. Oh D., Haffey P., Patel A., Gulati A. Intravenous Ketamine for Cancer Pain Management Including Flares During the COVID-19 Pandemic: A Retrospective Study. Pain Med. 2021;22:1642–1650. doi: 10.1093/pm/pnab163.
    1. Kumar A., Kohli A. Comeback of ketamine: Resurfacing facts and dispelling myths. Korean J. Anesthesiol. 2021;74:103–114. doi: 10.4097/kja.20663.
    1. Gupta H., Patel A., Eswani Z., Moore P., Steib M., Lee C., Kaye A.D. Role of Intravenous Lidocaine Infusion in the Treatment of Peripheral Neuropathy. Orthop. Rev. 2021;13:1–13. doi: 10.52965/001c.25567.
    1. Moulin D.E., Morley-Forster P.K., Pirani Z., Rohfritsch C., Stitt L. Intravenous lidocaine in the management of chronic peripheral neuropathic pain: A randomized-controlled trial. Can. J. Anesth. 2019;66:820–827. doi: 10.1007/s12630-019-01395-8.
    1. Liu Q., Gao L.L., Dai Y.L., Li Y.X., Wang Y., Bai C.F., Mu G.X., Chai X.M., Han W.J., Zhou L.J., et al. Nitrous oxide/oxygen mixture for analgesia in adult cancer patients with breakthrough pain: A randomized, double-blind controlled trial. Eur. J. Pain. 2018;22:492–500. doi: 10.1002/ejp.1144.
    1. Hagen N.A., Fisher K., Stiles C. Sublingual methadone for the management of cancer-related breakthrough pain: A pilot study. J. Palliat. Med. 2007;10:331–337. doi: 10.1089/jpm.2006.0163.
    1. Simon S.M., Schwartzberg L.S. A review of rapid-onset opioids for breakthrough pain in patients with cancer. J. Opioid Manag. 2014;10:207–215. doi: 10.5055/jom.2014.0209.
    1. Woo K.Y. Meeting the challenges of wound-associated pain: Anticipatory pain, anxiety, stress, and wound healing. Ostomy Wound Manag. 2008;54:10–12.
    1. Choi E.J., Choi Y.M., Jang E.J., Kim J.Y., Kim T.K., Kim K.H. Neural ablation and regeneration in pain practice. Korean J. Pain. 2016;29:3. doi: 10.3344/kjp.2016.29.1.3.
    1. Waldman S.D. Atlas of Interventional Pain Management. 4th ed. Elsevier; Philadelphia, PA, USA: 2015.
    1. Maida V., Ennis M., Kuzienisky C., Trozzolo L. Symptoms associated with malignant wounds: A prospective case study. J. Pain Symptom Manag. 2009;37:206–211. doi: 10.1016/j.jpainsymman.2008.01.009.
    1. Cevikbas F., Lerner E.A. Physiology and pathophysiology of itch. Physiol. Rev. 2020;100:945–982. doi: 10.1152/physrev.00017.2019.
    1. Parnell L.K.S. Itching for knowledge about wound and scar pruritus. Wounds. 2018;30:17–26.
    1. Huguen J., Brenaut E., Clerc C.J., Poizeau F., Marcorelles P., Quereux G., Dupuy A., Misery L. Comparison of characteristics of neuropathic and non-neuropathic pruritus to develop a tool for the diagnosis of neuropathic pruritus: The NP5. Front. Med. 2019;6:79. doi: 10.3389/fmed.2019.00079.
    1. Andrade A., Kuah C.Y., Martin-Lopez J.E., Chua S., Shpadaruk V., Sanclemente G., Franco J.V. Interventions for chronic pruritus of unknown origin. Cochrane Database Syst. Rev. 2020;1:1–71. doi: 10.1002/14651858.CD013128.pub2.
    1. Gibson S., Green J. Review of patients’ experiences with fungating wounds and associated quality of life. J. Wound Care. 2013;22:265–275. doi: 10.12968/jowc.2013.22.5.265.
    1. Bolton L. Evidence Corner: Evidence-based Care for Malignant Wounds. Wounds. 2016;28:214–216.
    1. Ramasubbu D.A., Smith V., Hayden F., Cronin P. Systemic antibiotics for treating malignant wounds. Cochrane Database Syst. Rev. 2017;8:1–23. doi: 10.1002/14651858.CD011609.pub2.
    1. Tremblay D., Roberge D., Touati N., Maunsell E., Berbiche D. Effects of interdisciplinary teamwork on patient-reported experience of cancer care. BMC Health Serv. Res. 2017;17:218. doi: 10.1186/s12913-017-2166-7.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅